Lymphoma and the Immunocompromised Host

Publisher Website
Google Scholar
Abstract
To the Editor: We were intrigued by the report by Gossett et al. in the April 19 issue of a monoclonal immunoblastic sarcoma of donor origin, which developed within three months of the onset of graft-versus-host disease in an allogeneic bone-marrow-transplant recipient. If it is safe to assume that a similar tumor has not and will not in the near future develop in the donor, this case provides evidence that the immunologic milieu may be a critical variable in the pathogenesis of this rare lymphoma.To the authors' list of immune-related disorders associated with malignant lymphomas we would like to . . .